. et al. Hypoxanthine derivatives in experimental infections. Can J Infect Dis 1992;3(Suppl B): 106B-110B. In vivo treatment with parenterally administered hypoxanthine derivatives. n otably ST 789, was able to protect cyclophosphamide-immunosuppressed mice against experimental infections with both bacterial and fungal pathogens. However, the mechanisms accou nting for these effects of hypoxanthine derivatives remain to be fully established. In fact. only the treatment with ST 789 resulted in a clear enhancement of the primary antibody production as well as macrophage phagocytic activity, whereas T lymphocyte responsiveness to mitogens and both macrophage-and natural killer-dependent cytotoxicity were not significanUy affected. These data. together with the recently shown ability of ST 789 to increase interleukin-6 production, suggest that monocyte/macrophages are likely to be the main cell ular target of the imrnunomodulaUng activity of ST 789. Finally, in the presentln vivo study, hypoxanthine derivatives did not enhance the mean survival lime of tumour-bearing immunosuppressed mice.
S EVERAL RECENT REPORTS SUGGESTED THAT ARGININE AND
arginine-containing hypoxanthine derivatives can strongly modulate immune functions both in vitro (l ,2) and in vivo (1, (3) (4) (5) . ST 789, which has a pentyloxycarbonil-L-arginine residue at the N-9 position of the hypoxanthine ring, strongly enhanced in vitro interleukin-6 (IL-6) production by mitogen-driven peripheral blood mononuclear cells (6) as well as T lymphocyte responsiveness to mitogens (7, 8) and natural killer-and macrophage-dependent cytotoxicity (1, 4, 5, 9) . Furthermore, cyclophosphamide-immunosuppressed mice injected with ST 789 were more resistant to experimental infections from both bacterial and fungal pathogens (I 0, 11) .
Several arginine-containing hypoxanthine derivatives are currently available. The main difference between ST 789 and its derivatives is that the derivatives, instead of having a terminal L-arg aminoacidic residue, possess an L-arg terminal peptide of varying length (two to five aminoacidic residues). However, reports evaluating both in vitro and in vivo immunomodulating properties of the derivatives are currently lacking. In contrast, ST 789 has been evaluated extensively in this respect. The present study found that, as a group, hypoxanthine derivatives other than ST 789 are not very potent immune modulators. However, after treatment with many hypoxanthine derivatives (including ST 789) experimentally infected mice were protected against challenge with several pathogens. Finally, while ST 789 had some antitumour activity, the other derivatives evaluated did not 3 ) and Pseudomonas aeruginosa (1x10 10 ) were inoculated intraperitoneally, and Candida albicans (5x 10 5 ) and Aspergillus fumigatus (5x 1 0 6 ) were inoculated intravenously in cyclophosphamide-immunosuppressed mice. Cyclophosphamide was administered intraperitoneally at dosages ranging from 50 to 150 mg/ kg five days before the induction of infection and approximately 2 h before starting hypoxanthine derivative treatment, which was given for five consecutive days. In the P aeruginosa model cyclophosphamide was administered two days prior to challenge. As previously reported (12, 13 Control cultures without antigen were set up in several experiments. The cultures were incubated at 37°C in 5% carbon dioxide for 90 mins. The cells were washed, resuspended in medium and assayed for plaque-forming cells by using the previously described slide modification of the hemolysis in gel method (14) . T lymphocyte proliferation to mitogens: T lymphocyte proliferative responsiveness to mitogens was assayed as previously described (15) . Spleen cells were obtained from mice given five days of therapy with hypoxanthine derivatives. Delayed T hypersensitivity reactions: Delayed T hypersensitivity reactions were assayed as previously reported (16) . Macrophage-dependent cytotoxicty: Peritoneal exudate cells were obtained by washing the abdominal cavity of B6D2F1 mice with RPM! 1640. Harvested cells, were centrifuged at 400 g for 10 mins at 4°C and density adjusted to 2x10 6 cells/rnL. Daudi cells were used as target cells. The cytotoxicity test was performed as previously described (5).
MATERIALS AND METHODS
Phagocytic activity: The phagocytic activity of peritoneal exudate cells was assayed as previously reported (17) . Briefly, peritoneal exudate cells were adjusted to a density of 4X10 6 cells/mL to which was added sheep red bloods cells previously opsonized with anti-sheep erythrocyte immunoglobulins. After 1 h incubation at 37°C in 5% carbon dioxide, nonphagocytosed erythrocytes were removed using hypotonic saline solution. Natural killer cell-dependent cytotoxicity: The assay of natural killer cell activity was performed using standard methods (18) . Antitumoral activity: Antitumoral activity was assayed as previously described (19) . Br;efly, inbred C57B1/6 (age eight weeks) and DBA/2 (age six weeks) male mice were used in the experiments with both carcinoma and leukemia models. Outbred CD 1 male 
RESULTS

Experiment al infections:
All hypoxanthine derivatives tested were able to protect cyclophosphamide-treated mice against experimental infections with both bacterial and fungal pathogens as shown by improvement in both percentage mortality and mean survival time. In the K oxytoca, S marcescens and S typhimurium infective models, ST 789 was most effective when administered intraperitoneally. as it proved active at concentrations as low as 0.25 mg/kg (Tables 1,2) . Similar results were obtained in K pneumoniae, E coli and Ps mirabilis models (data not shown).
In contrast. subcutaneous administrations of the immunomodulator were able to protect mice against only P aeruginosa and C albicans infections, the former occurring when ST 789 was administered alone or in the association with gentamicin (data not shown). and the latter occurring when ST 789 was combined with an 'ineffective' dosage of amphotericin B ( T lymphocyte responsiveness to mitogens: None of the hypoxanthine derivatives affected lymphocyte proliferation following stimulation with mitogens, such as phytohemagglutinin, lipopolysaccharide and concanavalinA. A slight but not significant reduction of mitogendriven lymphocyte proliferation was found in mice administered ST 657. Overall, these data support previous experiments performed in the authors' laboratory indicating that ST 789 is not able to enhance in vitro the surface expression of activation antigens. such as IL-2 and transferrin receptors, as well as IL-2 and interferongamma production by phytohemagglutinin-stimulated peripheral blood mononuclear cells (6, 20) . Delayed T cell hyperreactivity reactions: None of the hypoxanthine derivatives investigated significantly affected delayed T cell hyperreactivity reactions. 
DISCUSSION
The results clearly show that hypoxanthine derivatives, most notably ST 789, exhibit immunomodulaling properties. In fact, this group of molecules protected cyclophosphamide-immunosuppressed mice against experimental infections with bacterial and fungal pathogens, confirming previous reports (10, 11 antimicrobial agents, such as ceftazidime, amphotericin B and gentamicin. at doses per se completely ineffective, strongly protected cyclosphosphamidetreated mice in several models of experin1ental infections. Therefore, ST 789 either alone or in combination with antibiotics enhances host resistance to pathogens.
The mechanisms responsible for these effects of hypoxanthine derivatives are unclear. The reported ability of ST 789 to restore mitogen responsiveness of lymphocytes from cyclophosphamide-treated mice is likely to play a major role (21) . However, other cells could mediate the immunomodulating activity of ST 789. In fact, ST 789 treatment expanded bone marrow natural killer progenitor cells in vivo, thus strongly enhancing the regeneration of mouse natural killer cell activity (9) . Furthermore, as cyclophosphan1ide treatment severely reduces the number of circulating granulocytes (22) , the capacity of hypoxanthine derivatives to protect cyclophosphamide-administered mice against pathogens might -at least in part-depend on their myelorestorative ability. However, a role for colony stimulating factors in mediating the immunomodulation of hypoxanthine derivatives is still unproven.
Data from the authors' laboratory showing an increased in vitro production of IL-6 by peripheral blood mononuclear cells cultured in the presence of both mitogens and ST 789 compared with control cultures suggest that hypoxanthine derivatives could act in vivo by modulating cytokine production (6) . Furthermore, the present report shows that in vivo administered ST 789, as well as other hypoxanthine derivatives, strongly enhanced the phagocytic activity of peritoneal exudate macrophages. Since macrophages are the main cellular source of IL-6 (23) this suggests that hypoxanthine derivatives exert an action on monocytes/macrophages. Overall, these findings suggest that hypoxanthine derivatives could modulate infections with intracellular pathogens such as listeria, legionella, brucella, salmonella and mycobacteria.
A temporal relationship in cytokine production has been recently demonstrated for tumour necrosis factor, IL-l and IL-6 production (24). After a bacterial challenge, the appearance of IL-6 follows that of tumour necrosis factor and IL-2 during endotoxemia (25, 26) . Thus, the most likely scheme of activation leading to cytokine production involves the early release of tumour necrosis factor and IL-l from monocytes/macrophages which subsequently induces the secretion of IL-6 and other cytokines from both monocytes and structural cells, such as fibroblasts and endothelial cells. This cascade is the basis for the finding of sequential elevations of cytokines in plasma in experimental models of inflammation (25) (26) (27) .
The role of tumour necrosis factor in mediating the ST 789-dependent increase of IL-6 production remains to be established. Furthermore, there is no report on the ability of hypoxanthine derivatives other than ST 789 to modulate cytokine release in vivo or in vitro. In this study, these compounds exhibited immunomodulating activity in vivo. However, the in vitro lymphocyte responsiveness to mitogens, natural killer cell activity and delayed T cell hyperreactivity reactions were not significantly affected. Only ST 789 was able to increase the primary in vitro antibody production compared with other hypoxanthine derivatives. possibly by increasing IL-6 production (6). Therefore, the mechanisms involved in determining enhanced host resistance by hypoxanthine derivatives are sWl unresolved.
Finally, in the present study hypoxanthine derivatives did not show any in vivo antitumour activity. The results are in contradiction with previous reports in-
